Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Repeated dose toxicity: inhalation

Currently viewing:

Administrative data

Endpoint:
repeated dose toxicity: inhalation
Remarks:
other: inhaltion exposure for 2 months
Type of information:
experimental study
Adequacy of study:
other information
Reliability:
4 (not assignable)
Rationale for reliability incl. deficiencies:
other: only 1 concentration used anf therefore insufficient for assessment

Data source

Reference
Reference Type:
publication
Title:
Toxicity of cyclohexylamine and dicyclohexylamine
Author:
Lomonova GV
Year:
1963
Bibliographic source:
Gig Trud. Prof. Zabol. 7, 51-56 [Transl Suppl 24, T96-T98]

Materials and methods

Principles of method if other than guideline:
Exposure of CHA vapours in a concentration of 700 mg/m³ to rats for 2 hr daily for 2 months
GLP compliance:
no
Limit test:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
Cyclohexylamine
EC Number:
203-629-0
EC Name:
Cyclohexylamine
Cas Number:
108-91-8
Molecular formula:
C6H13N
IUPAC Name:
cyclohexanamine
Details on test material:
colorless liquid with strong odor and bitter taste, density: 0.86, boiling point 133 °C

Test animals

Species:
rat
Strain:
not specified
Sex:
not specified
Details on test animals or test system and environmental conditions:
no data

Administration / exposure

Route of administration:
inhalation
Type of inhalation exposure:
not specified
Vehicle:
air
Remarks on MMAD:
MMAD / GSD: no data
Details on inhalation exposure:
Exposure of CHA vapours in a concentration of 700 mg/m³ to rats for 2 hr daily for 2 months
Analytical verification of doses or concentrations:
not specified
Duration of treatment / exposure:
2 months
Frequency of treatment:
2 h daily
Doses / concentrations
Remarks:
Doses / Concentrations:
700 mg/m3
Basis:

No. of animals per sex per dose:
6 test animals and 6 controls
Control animals:
yes
Details on study design:
Exposure of CHA vapours in a concentration of 700 mg/m³ to rats for 2 hr daily for 2 months: Post-exposure period: no
Positive control:
no

Examinations

Observations and examinations performed and frequency:
The rats were weighed every 10 days and body temperature was recorded. general urinalysis was cartried out twice a months and general blood analysis once a month. Prothrombin time and , at the end of the inhalation period, oxygen consumption were determined
Sacrifice and pathology:
at the end of the inhalation period the rats were sacrificed to determine the weight of the organs and for histological examination
Other examinations:
no data
Statistics:
no data

Results and discussion

Results of examinations

Clinical signs:
effects observed, treatment-related
Mortality:
mortality observed, treatment-related
Body weight and weight changes:
effects observed, treatment-related
Food consumption and compound intake (if feeding study):
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
effects observed, treatment-related
Clinical biochemistry findings:
effects observed, treatment-related
Urinalysis findings:
effects observed, treatment-related
Behaviour (functional findings):
not examined
Organ weight findings including organ / body weight ratios:
effects observed, treatment-related
Gross pathological findings:
not specified
Histopathological findings: non-neoplastic:
effects observed, treatment-related
Histopathological findings: neoplastic:
no effects observed
Details on results:
RS-Freetext:
3/6 rats died towards the end of inhalation period;
decline in body temperature; reduction in respiratory rate;
loss of weight;
reduction in hemoglobin and erythrocytes by the end of second month; increase in reticulocytes;
reduction in the functional activity of the thyroid;
increased vascular permeability of arteries and arterioles,
fatty and granular degeneration of the myocardium and kidneys,
inflammatory changes of the trachea and lungs

Effect levels

Dose descriptor:
conc. level:
Effect level:
700 mg/m³ air
Sex:
not specified

Target system / organ toxicity

Critical effects observed:
not specified

Applicant's summary and conclusion